Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Neurology

Background:

• Selective serotonin reuptake inhibitors (SSRIs) can cause motor side effects via 5-HT2 receptor stimulation in the basal ganglia.
• Serotonin's inhibition of dopamine release is implicated in these motor side effects.
• Nefazodone, a serotonin antagonist/reuptake inhibitor (SARI), selectively blocks 5-HT2 receptors.

Purpose of the Study:

• To investigate nefazodone's dual efficacy as an antidepressant and a reducer of extrapyramidal symptoms in Parkinson disease (PD) patients.
• To compare nefazodone with fluoxetine in treating depression and motor symptoms in PD.

Main Methods:

• A randomized trial comparing nefazodone and fluoxetine in depressed PD patients.
• Patients were assessed by psychiatrists and neurologists using standardized scales.
• Evaluations included the Unified Parkinson Disease Rating Scale (UPDRS) and Beck Depression Inventory (BDI).

Main Results:

• Nefazodone significantly improved total UPDRS and UPDRS part III scores over time (P = 0.004, P = 0.003).
• Fluoxetine did not alter UPDRS scores in the PD patients.
• Both nefazodone and fluoxetine equally improved Beck Depression Inventory scores (P < 0.001).

Conclusions:

• Nefazodone demonstrates potential for dual action in depressed PD patients, improving both mood and motor symptoms.
• Nefazodone may be a preferable treatment over fluoxetine for depressed PD patients due to its beneficial effect on extrapyramidal symptoms.
• Further large-scale clinical trials are warranted to confirm these findings.